ULAŞ KAHYA, B. Et Al. 2023. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. The New England journal of medicine , vol.389, no.5 , 476.

ULAŞ KAHYA, B., ÖZDEMİR, N., & YAZICI, O., (2023). Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. The New England journal of medicine , vol.389, no.5, 476.

ULAŞ KAHYA, BURCU, NURİYE ÖZDEMİR, And OZAN YAZICI. "Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma," The New England journal of medicine , vol.389, no.5, 476, 2023

ULAŞ KAHYA, BURCU U. Et Al. "Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma." The New England journal of medicine , vol.389, no.5, pp.476, 2023

ULAŞ KAHYA, B. ÖZDEMİR, N. And YAZICI, O. (2023) . "Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma." The New England journal of medicine , vol.389, no.5, p.476.

@article{article, author={BURCU ULAŞ KAHYA Et Al. }, title={Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma}, journal={The New England journal of medicine}, year=2023, pages={476} }